Loading stock data…
$7.21-0.03 (-0.35%)
Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States.
Ocular Therapeutix, Inc. in the Healthcare sector is trading at $7.21 with a market capitalization of $2.5B. Wall Street consensus targets $26.00 (12 analysts), implying a +260.4% move over the next 12 months. The stock is currently near its 52-week low of $6.23, remaining 23.2% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the safe zone. Risk note: RSI 21 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 75/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $13.47M↑ | $10.79M↓ | $13.25M↓ | $14.54M↑ | $13.46M |
| Gross Profit | $11.46M↑ | $9.46M↓ | $11.66M↓ | $12.77M↑ | $11.52M |
| Operating Income | -$82.11M↑ | -$93.34M↓ | -$69.76M↓ | -$68.70M↓ | -$67.64M |
| Net Income | -$78.76M↑ | -$88.61M↓ | -$64.65M↑ | -$69.42M↓ | -$67.81M |
Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The...